RCAN1 in cardiovascular diseases: molecular mechanisms and a potential therapeutic target.

Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. Considerable efforts are needed to elucidate the underlying mechanisms for the prevention and treatment of CVDs. Regulator of calcineurin 1 (RCAN1) is involved in both development/maintenance of the cardiovascular system and the pathogenesis of CVDs. RCAN1 reduction protects against atherosclerosis by reducing the uptake of oxidized low-density lipoproteins, whereas RCAN1 has a protective effect on myocardial ischemia/reperfusion injury, myocardial hypertrophy and intramural hematoma/aortic rupture mainly mediated by maintaining mitochondrial function and inhibiting calcineurin and Rho kinase activity, respectively. In this review, the regulation and the function of RCAN1 are summarized. Moreover, the dysregulation of RCAN1 in CVDs is reviewed. In addition, the beneficial role of RCAN1 reduction in atherosclerosis and the protective role of RCAN1 in myocardial ischemia/reperfusion injury, myocardial hypertrophy and intramural hematoma /aortic rupture are discussed, as well as underlying mechanisms. Furthermore, the therapeutic potential and challenges of targeting RCAN1 for CVDs treatment are also discussed.

Optimal Design of Multi-Scale Fibre-Reinforced Cement-Matrix Composites Based on an Orthogonal Experimental Design.

Cement-matrix composite are typical multi-scale composite materials, the failure process has the characteristics of gradual, multi-scale and multi-stage damage. In order to delay the multi-stage damage process of cement-matrix composites, the defects of different scales are suppressed by using different scales of fibres and fly ash (FA), and the overall performance of cement-matrix composites is improved, a new multi-scale fibre-reinforced cement-based composite composed of millimetre-scale polyvinyl alcohol fibre (PVA), micron-scale calcium carbonate whisker (CW), and nano-scale carbon nanotubes (CNTs) was designed in this study. The compressive strength, flexural strength, splitting tensile strength, and chloride ion permeability coefficient were used as assessment indices by the orthogonal test design. The impacts of the three fibre scales and fly ash on each individual index were examined, and the overall performance of the multi-scale fibre-reinforced cementitious materials (MSFRCC) was then optimized using grey correlation analysis. The optimized mix ratio for overall performance was PVA: 1.5%, CW: 2%, CNTs: 0.1%, FA: 40%. Compared with the optimal results for each group, the compressive strength of the final optimized MSFRCC group decreased by 8.9%, the flexural strength increased by 28.4%, the splitting tensile strength increased by 10%, and the chloride ion permeability coefficient decreased by 5.7%. The results show that the compressive performance and resistance to chloride ion penetration of the optimized group are slightly worse than those of the optimal group in the orthogonal test, but its flexural performance and splitting tensile performance are significantly improved.

Optimisation of the Mechanical Properties and Mix Proportion of Multiscale-Fibre-Reinforced Engineered Cementitious Composites.

Engineered cementitious composites (ECCs) are cement-based composite materials with strain-hardening and multiple-cracking characteristics. ECCs have multiscale defects, including nanoscale hydrated silicate gels, micron-scale capillary pores, and millimetre-scale cracks. By using millimetre-scale polyethylene (PE) fibres, microscale calcium carbonate whiskers (CWs), and nanoscale carbon nanotubes (CNTs) as exo-doped fibres, a multiscale enhancement system was formed, and the effects of multiscale fibres on the mechanical properties of ECCs were tested. The Box-Behnken experimental design method, which is a response surface methodology, was used to construct a quadratic polynomial regression equation to optimise ECC design and provide an optimisation of ECC mix proportions. The results of this study showed that a multiscale reinforcement system consisting of PE fibres, CWs, and CNTs enhanced the mechanical properties of ECCs. CWs had the greatest effect on the compressive strengths of highly ductile-fibre-reinforced cementitious composites, followed by CNTs and PE fibres. PE fibres had the greatest effect on the flexural and tensile strengths of high-ductility fibre-reinforced cementitious composites, followed by CWs and CNTs. The final optimisation results showed that when the ECC matrix was doped with 1.55% PE fibres, 2.17% CWs, and 0.154% CNTs, the compressive strength, flexural strength, and tensile strength of the matrix were optimal.

RCAN1 Inhibits BACE2 Turnover by Attenuating Proteasome-Mediated BACE2 Degradation.

Amyloid-ß protein (Aß) is the main component of neuritic plaques, the pathological hallmark of Alzheimer's disease (AD). ß-site APP cleaving enzyme 1 (BACE1) is a major ß-secretase contributing to Aß generation. ß-site APP cleaving enzyme 2 (BACE2), the homolog of BACE1, is not only a θ-secretase but also a conditional ß-secretase. Previous studies showed that regulator of calcineurin 1 (RCAN1) is markedly increased by AD and promotes BACE1 expression. However, the role of RCAN1 in BACE2 regulation remains elusive. Here, we showed that RCAN1 increases BACE2 protein levels. Moreover, RCAN1 inhibits the turnover of BACE2 protein. Furthermore, RCAN1 attenuates proteasome-mediated BACE2 degradation, but not lysosome-mediated BACE2 degradation. Taken together, our work indicates that RCAN1 inhibits BACE2 turnover by attenuating proteasome-mediated BACE2 degradation. It advances our understanding of BACE2 regulation and provides a potential mechanism of BACE2 dysregulation in AD.

BACE2 degradation is mediated by both the proteasome and lysosome pathways.

BACKGROUND: Alzheimer's disease is the most common neurodegenerative disease in the elderly. Amyloid-ß protein (Aß) is the major component of neuritic plaques which are the hallmark of AD pathology. ß-site APP cleaving enzyme 1 (BACE1) is the major ß-secretase contributing to Aß generation. ß-site APP-cleaving enzyme 2 (BACE2), the homolog of BACE1, might play a complex role in the pathogenesis of Alzheimer's disease as it is not only a θ-secretase but also a conditional ß-secretase. Dysregulation of BACE2 is observed in Alzheimer's disease. However, the regulation of BACE2 is less studied compared with BACE1, including its degradation pathways. In this study, we investigated the turnover rates and degradation pathways of BACE2 in both neuronal cells and non-neuronal cells. RESULTS: Both lysosomal inhibition and proteasomal inhibition cause a time- and dose-dependent increase of transiently overexpressed BACE2 in HEK293 cells. The half-life of transiently overexpressed BACE2 protein is approximately 6 h. Moreover, the half-life of endogenous BACE2 protein is approximately 4 h in both HEK293 cells and mouse primary cortical neurons. Furthermore, both lysosomal inhibition and proteasomal inhibition markedly increases endogenous BACE2 in HEK293 cells and mouse primary cortical neurons. CONCLUSIONS: This study demonstrates that BACE2 is degraded by both the proteasome and lysosome pathways in both neuronal and non-neuronal cells at endogenous level and in transient overexpression system. It indicates that BACE2 dysregulation might be mediated by the proteasomal and lysosomal impairment in Alzheimer's disease. This study advances our understanding of the regulation of BACE2 and provides a potential mechanism of its dysregulation in Alzheimer's disease.

TMP21 in Alzheimer's Disease: Molecular Mechanisms and a Potential Target.

Alzheimer's disease (AD) is the most common form of dementia in the elderly, which is characterized by progressive cognitive impairment. Neuritic plaques, neurofibrillary tangles and neuronal loss are the major neuropathological hallmarks in AD brains. TMP21 is a key molecule for protein trafficking in cells. Growing evidence indicates that TMP21 is dysregulated in AD, which plays a pivotal role in neuritic plaque formation. Therefore, we aim to review the dysregulation of TMP21 in AD, the role of TMP21 in neuritic plaque formation and underlying mechanisms. Moreover, the potential role of TMP21 in neurofibrillary tangle formation, synaptic impairment and neuronal loss is discussed. It will provide an outlook into the potential of regulating TMP21 as a therapeutic approach for AD treatment.

Proteasome Inhibition Activates Autophagy-Lysosome Pathway Associated With TFEB Dephosphorylation and Nuclear Translocation.

Ubiquitin-proteasome pathway (UPS) and autophagy-lysosome pathway (ALP) are the two major protein degradation pathways, which are critical for proteostasis. Growing evidence indicates that proteasome inhibition-induced ALP activation is an adaptive response. Transcription Factor EB (TFEB) is a master regulator of ALP. However, the characteristics of TFEB and its role in proteasome inhibition-induced ALP activation are not fully investigated. Here we reported that the half-life of TFEB is around 13.5 h in neuronal-like cells, and TFEB is degraded through proteasome pathway in both neuronal-like and non-neuronal cells. Moreover, proteasome impairment not only promotes TFEB accumulation but also facilitates its dephosphorylation and nuclear translocation. In addition, proteasome inhibition-induced TFEB accumulation, dephosphorylation and nuclear translocation significantly increases the expression of a number of TFEB downstream genes involved in ALP activation, including microtubule-associated protein 1B light chain-3 (LC3), particularly LC3-II, cathepsin D and lysosomal-associated membrane protein 1 (LAMP1). Furthermore, we demonstrated that proteasome inhibition increases autophagosome biogenesis but not impairs autophagic flux. Our study advances the understanding of features of TFEB and indicates that TFEB might be a key mediator of proteasome impairment-induced ALP activation.

Orexin-A protects against oxygen-glucose deprivation/reoxygenation-induced cell damage by inhibiting endoplasmic reticulum stress-mediated apoptosis via the Gi and PI3K signaling pathways.

The neuropeptide orexin-A (OXA) has a neuroprotective effect, acting as an anti-apoptotic factor in response to multiple stimuli. Apoptosis induced by endoplasmic reticulum stress (ERS) underlies oxygen-glucose deprivation and reoxygenation (OGD/R)-induced cell damage, an in vitro model of ischemia/reperfusion injury. However, that OXA inhibits ERS-induced apoptosis in the OGD/R model has not been reported. In the present study, we investigated the neuroprotective effect of OXA (0.1 µM) on OGD/R-induced damage in the human neuroblastoma cell line SH-SY5Y. After OXA treatment following 4 h oxygen-glucose deprivation (OGD) and then 4 h reoxygenation (R), cell morphology, viability, and apoptosis were analyzed by histology, Cell Counting Kit-8 assay, and flow cytometry, respectively. Western blotting was used to measure expression levels of ERS- and apoptosis-related proteins. To determine signaling pathways involved in OXA-mediated neuroprotection, the Gi pathway inhibitor pertussis toxin (PTX; 100 ng/mL) and PI3K inhibitor LY294002 (LY; 10 µM) were added. In addition, in order to prove the specificity of these characteristics, the OXA antagonist Suvorexant (DORA; Ki of 0.55 nM and 0.35 nM for OX1R and OX2R) was used for intervention. Our results showed that OGD/R induced cell damage, manifested as morphological changes and a significant decrease in viability. Furthermore, Western blotting detected an increase in ERS-related proteins GRP78, p-IRE1α, p-JNK, and Cleaved caspase-12, as well as apoptosis-related proteins Cleaved caspase-3 and Bax, and a decrease in the anti-apoptosis factor Bcl-2. OXA intervention alleviated the degree of cellular damage, and protein expression was also reversed. In addition, the protective effect of OXA was reduced by adding PTX and LY. Meanwhile, after the use of DORA, changes in the expression of related proteins were detected, and it was found that the protective effect of OXA was weakened. Collectively, our results indicate that OXA has a neuroprotective effect on OGD/R-induced cell damage by inhibiting ERS-induced apoptosis through the combined action of Gi and PI3K signaling pathways. These findings help to clarify the mechanism underlying the neuroprotective action of OXA, which should aid the development of further candidate drugs, and provide a new therapeutic direction for the treatment of ischemic stroke.